Retraction: A Short Caspase-3 Isoform Inhibits Chemotherapy-Induced Apoptosis by Blocking Apoptosome Assembly (PLoS ONE (2011) 6: 12 (E29058) DOI: 10.1371/journal.pone.0029058);A short caspase-3 isoform inhibits chemotherapy-induced apoptosis by blocking apoptosome assembly

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Végran, Frédérique ^a,b,c   Boidot, Romain ^a,b   Solary, Eric ^b,c   Lizard Nacol, Sarab ^a,b  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Chu   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FODRIN; ANTINEOPLASTIC AGENT; APOPTOSOME; CASPASE; CASPASE 3; CASPASE 3S; CASPASE 9; ETOPOSIDE; LAMIN A; MEMBRANE PROTEIN; METHOTREXATE; PROCASPASE 3; UNCLASSIFIED DRUG; VINBLASTINE; ISOENZYME; PRIMER DNA;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; AMINO ACID SEQUENCE; BREAST TUMOR; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; APOPTOSIS; APOPTOSOMES; BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; DNA PRIMERS; ENZYME ACTIVATION; HUMANS; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84055182529     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0306366     Document Type: Erratum

References (33)

1. Johnstone RW, Ruefli AA, Lowe SW, (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-154.
2. Porter AG, Jänicke RU, (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104.
3. Mercatante D, Kole R, (2000) Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol Ther 85: 237-243.
4. Seol DW, Billiar TR, (1999) A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J Biol Chem 274: 2072-2076.
5. Huang Y, Shin NH, Sun Y, Wang KK, (2001) Molecular cloning and characterization of a novel caspase-3 variant that attenuates apoptosis induced by proteasome inhibition. Biochem Biophys Res Commun 283: 762-769.
6. Végran F, Boidot R, Oudin C, Riedinger JM, Bonnetain F, et al. (2006) Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res 12: 5794-5800.
7. Horvitz HR, Sternberg PW, Greenwald IS, Fixsen W, Ellis EM, (1983) Mutations that affect neural cell lineages and cell fates during the development of the nematode Caenorhabditis elegans. Cold Spring Harb Symp Quant Biol 48: 453-463.
8. Jänicke RU, Ng P, Sprengart ML, Porter AG, (1998) Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other substrates in apoptosis. J Biol Chem 273: 9357-9360.
9. Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, et al. (2001) Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 61: 348-354.
10. Bellarosa D, Ciucci A, Bullo A, Nardelli F, Manzini S, et al. (2001) Apoptotic events in a human ovarian cancer cell ine exposed to anthracyclines. J Pharmacol Exp Ther 296: 276-283.
11. Kwon KB, Park EK, Ryu DG, Park BH, (2002) D4-GDI is cleaved by caspase-3 during daunorubicin-induced apoptosis in HL-60 cells. Exp Mol Med 34: 32-37.
12. Rozalski M, Mirowski M, Balcerczak E, Krajewska U, Mlynarski W, et al. (2005) Induction of caspase-3 activity, bcl-2 bax and p65 gene expression modulation in human acute promyelocytic leukemia HL-60 cells by doxorubicin with amifostine. Pharmacol Rep 57: 360-366.
13. Henkels KM, Turchi JJ, (1999) Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 59: 3077-3083.
14. Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, et al. (2000) Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 60: 4386-4390.
15. Cummings BS, Schnellmann RG, (2002) Cisplatin-induced renal cell apoptosis: caspase-3-dependent and -independent pathways. J Pharmacol Exp Ther 302: 8-17.
16. Kishimoto S, Kawazoe Y, Ikeno M, Fukushima S, Takeuchi Y, (2005) Continuous exposure to low-dose cisplatin and apoptosis. Biol Pharm Bull 28: 1954-1957.
17. Tenev T, Marani M, McNeish I, Lemoine NR, (2001) Pro-caspase-3 overexpression sensitizes ovarian cancer cells to proteasome inhibitors. Cell Death Differ 8: 256-264.
18. Ofir R, Seidman R, Rabinski T, Krup M, Yavelsky V, et al. (2002) Taxol-induced apoptosis in human SKOV3 ovarian and MCF-7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ 9: 636-642.
19. Ibrado AM, Kim CN, Bhalla K, (1998) Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells. Leukemia 2: 1930-1936.
20. Kottke TJ, Blajeski AL, Martins LM, Mesner PW, Davidson NE, et al. Comparison of paclitaxel-, 5-fluoro-2′-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis. J Biol Chem 274: 15927-15936.
21. Samejima K, Svingen PA, Basi GS, Koktte T, Mesner PW, et al. (1999) Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis. J Biol Chem 274: 4335-4340.
22. Weigel TL, Lotze MT, Kim PK, Amoscato AA, Luketich JD, et al. (2000) Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity. J Thorac Cardiovasc Surg 199: 795-803.
23. Chen T, Pengetnze Y, Taylor CC, (2005) Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther 4: 217-224.
24. Kojima H, Endo K, Moriyama H, Tanaka Y, Alnmeri ES, et al. (1998) Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J Biol Chem 273: 16647-16650.
25. Kivinen K, Kallajoki M, Taimen P, (2005) Caspase-3 is required in the apoptotic disintegration of the nuclear matrix. Exp Cell Res 311: 62-73.
26. Hattangadi DK, DeMasters GA, Walkers TD, Jones KR, Newsham IF, et al. (2004) Influence of p53 and caspase-3 activity on cell death and senescence in response to methotrexate in the breast tumor cell. Biochem Pharmacol 68: 1699-1708.
27. Wei Y, Fox T, Chambers SP, Sintchak J, Coll JT, et al. (2000) The structures of caspases-1,-3,-7 and-8 reveal the basis for substrate and inhibitor selectivity. Chem Biol 7: 423-432.
28. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, et al. (2001) Structural basis for the inhibition of caspase-3 by XIAP. Cell 104: 791-800.
29. Bose K, Pop C, Feeney B, Clark AC, (2003) An uncleavable procaspase-3 mutant has a lower catalytic efficiency but an active site similar to that of mature caspase-3. Biochemistry 42: 12298-12310.
30. Yang S, Zhou Q, Yang X, (2007) Caspase-3 status is a determinant of the differential responses to genistein between MDA-MB-231 and MCF-7 breast cancer cells. Biochim Biophys Acta 1773: 903-9011.
31. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, et al. (1999) Ordering the cytochrom c-initiated caspase cascade: hierarchical activation of caspase-2,-3,-6,-7,-8, and-10 in a caspase-9-dependent manner. J Cell Biol 144: 281-292.
32. Wang P, Shi T, Ma D, (2006) Cloning of a novel human caspase-9 splice variant containing only the CARD domain. Life Sci 79: 934-940.
33. Mohr A, Zwacka RM, Jarmy G, Büneker C, Schrezenmeier H, et al. (2005) Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene 24: 2421-2429.